Casi Pharmaceuticals Inc (CASI)

$6.35

-0.21

(-3.2%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $6.32
    $6.69
    $6.35
    downward going graph

    0.46%

    Downside

    Day's Volatility :5.51%

    Upside

    5.08%

    downward going graph
  • $1.90
    $8.48
    $6.35
    downward going graph

    70.08%

    Downside

    52 Weeks Volatility :77.59%

    Upside

    25.12%

    downward going graph

Returns

PeriodCasi Pharmaceuticals IncIndex (Russel 2000)
3 Months
191.56%
0.0%
6 Months
37.53%
0.0%
1 Year
144.78%
0.0%
3 Years
-49.92%
-17.0%

Highlights

Market Capitalization
84.2M
Book Value
$1.16
Earnings Per Share (EPS)
-2.28
PEG Ratio
0.0
Wall Street Target Price
6.0
Profit Margin
-105.24%
Operating Margin TTM
-270.46%
Return On Assets TTM
-23.25%
Return On Equity TTM
-77.12%
Revenue TTM
28.9M
Revenue Per Share TTM
2.16
Quarterly Revenue Growth YOY
-59.199999999999996%
Gross Profit TTM
17.6M
EBITDA
-23.2M
Diluted Eps TTM
-2.28
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.56
EPS Estimate Next Year
-2.13
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Casi Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 5.51%

Current $6.35
Target $6.00

Technicals Summary

Sell

Neutral

Buy

Casi Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Casi Pharmaceuticals Inc
Casi Pharmaceuticals Inc
87.43%
37.53%
144.78%
-49.92%
-78.84%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Casi Pharmaceuticals Inc
Casi Pharmaceuticals Inc
NA
NA
0.0
-2.56
-0.77
-0.23
NA
1.16
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Casi Pharmaceuticals Inc
Casi Pharmaceuticals Inc
Buy
$84.2M
-78.84%
NA
-105.24%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Casi Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 15.25M → 3.40M (in $), with an average decrease of 30.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -4.63M → -9.52M (in $), with an average decrease of 46.2% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 244.2%

Institutional Holdings

  • Wellington Shields Capital Mgmt LLC

    0.69%
  • Wellington Shields & Co., LLC

    0.32%
  • Howland Capital Management Inc

    0.30%
  • Renaissance Technologies Corp

    0.27%
  • Geode Capital Management, LLC

    0.17%
  • JANE STREET GROUP, LLC

    0.09%

Company Information

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Organization
Casi Pharmaceuticals Inc
Employees
176
CEO
Dr. Wei-Wu He Ph.D.
Industry
Health Technology

FAQs